)
Company Research3 May 2024
Companies That Had Their IPO in 2019: Bull Market and Tech Dominance
Discussing the stock and IPO market in 2019, and the factors that led to the overall bullish performance of stocks during the year.
BioNTech
BioNTech (BNTX) investor relations material
BioNTech Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary10 Mar, 2026
Executive summary
Achieved strong COVID-19 vaccine market leadership with over 50% share in key markets, launched a variant-adapted vaccine, and maintained leadership while advancing a diversified oncology pipeline with late-stage assets and novel combinations, including pivotal programs in lung and breast cancer.
Advanced over 25 phase 2 & 3 oncology trials and 10 novel-combination trials, with strategic partnerships and acquisitions, and sharpened focus on late-stage oncology and next-generation mRNA innovations; CEO and CMO transitions planned by end of 2026.
Ended 2025 with €17.2 billion in cash, cash equivalents, and securities, supporting a robust pipeline and future launches.
Announced the creation of a new independent company for next-generation mRNA innovations, with founders transitioning by end of 2026; BioNTech to retain a minority stake and strategic collaboration opportunities.
Strategic partnerships, notably with BMS, and acquisitions of Biotheus and CureVac, strengthened the pipeline and de-risked key programs.
Financial highlights
FY 2025 revenues reached €2.87 billion, exceeding guidance (€2.6–2.8 billion), with Q4 2025 revenues at €907 million, down from €1.19 billion in Q4 2024.
FY 2025 IFRS net loss was €1.14 billion; adjusted net loss was €117 million.
R&D expenses for 2025 were €2.10 billion (adjusted: €2.02 billion), slightly lower than prior year due to portfolio management and BMS cost-sharing.
Ended 2025 with €17.2 billion in cash and securities, supporting continued investment in late-stage programs.
Other operating result for 2025: negative €903.7 million, mainly due to settlements, pipeline prioritization, and FX differences.
Outlook and guidance
FY 2026 revenue guidance: €2.0–2.3 billion, reflecting lower COVID-19 vaccine sales in US and Europe, partially offset by continued BMS collaboration payments.
Adjusted R&D expenses for 2026 projected at €2.2–2.5 billion, with increased investment in late-stage oncology and reduced spend outside priority areas.
SG&A expenses expected at €700–800 million, driven by commercial build-out for oncology launches.
Multiple late-stage oncology trial readouts and pivotal trial initiations expected in 2026.
No material short- or mid-term financial impact expected from the new mRNA company transaction.
Non-COVID revenue growth beyond 2026?
Strategic rationale for new mRNA innovation company?
Which 2026 readouts drive multi-product goal?
What specific mRNA tech transfers to new company?
Prioritize Pumitamig's 3-wave development plan.
Impact of Germany's COVID sales on top line?
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from BioNTech
- Q2 2024 revenue dropped to €128.7M, but oncology pipeline advanced and €18.5B cash was maintained.BNTX
Q2 20242 Feb 2026 - AI-driven supercomputing and generative models are transforming R&D and lab automation.BNTXAI Day 202420 Jan 2026
- Q3 2024 revenues surged on early COVID-19 vaccine launches and oncology pipeline advances.BNTXQ3 202417 Jan 2026
- Late-stage oncology launches and pivotal data in 2025–2026 drive growth and diversification.BNTXR&D Day 202414 Jan 2026
- Over 25 late-stage oncology trials and pivotal 2026 data, backed by strong financials.BNTX44th Annual J.P. Morgan Healthcare Conference14 Jan 2026
- Late-stage oncology and mRNA immunotherapies advance, with major data and launches expected from 2025.BNTX43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026
- Q1 2025 net loss widens as oncology pipeline advances and COVID-19 vaccine sales remain stable.BNTXQ1 202525 Dec 2025
- Late-stage oncology pipeline, strong partnerships, and key data in 2025–2026 drive growth.BNTXR&D Day16 Dec 2025
- 2024 net loss of €665m on €2.8bn revenue, oncology pipeline progress, and Biotheus acquisition.BNTXQ4 202412 Dec 2025
Next BioNTech earnings date
Q1 20265 May, 2026
BioNTech
Next BioNTech earnings date
Q1 20265 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. Additionaly its clinical development will target the treatment of infectious diseases, including prophylactic vaccine approach that includes mRNA. It is also developing various neoantigen-based immunotherapies in collaboration with Pfizer Inc.; other checkpoint molecules; and next-generation antigen receptor T-cell products. The company was formerly known as BioNtech Therapeutics GmbH. BioNTech SE was founded in 2008 and is headquartered in Mainz, Germany.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage